Mashhad University research on curcuminoids in patients with metabolic syndrome wins top prize
Dr Kalyanam, President R&D at Sabinsa, along with Dr Ajax Mohamed, Resident Director & Vice President, and Dr Umar Jan, were delighted to receive the Nutraingredients Best University Research of the Year award at Vitafoods Europe last week.
The company presented work from the Mashhad University of Medical Sciences by Y. Panahi, et al, describing the lipid-modifying effects of adjunctive therapy with curcuminoid-piperine combinations in patients with metabolic syndrome. The results of a randomised controlled trial were published in Complement. Ther. Med. in 2014.
Curcuminoids, well known for their anti-inflammatory activity and antioxidant activity, have also been considered as a natural alternative for managing lipid levels in patients with metabolic syndrome. This is the first study investigating the efficacy of curcuminoids in patients with metabolic syndrome (MS).
The 100-subject, randomised, double-blind, placebo-controlled parallel-group study concluded that the curcuminoid-piperine combination, supplied as Curcumin C3 Complex and BioPerine, from Sabinsa, is an efficacious adjunctive therapy in patients with MS and can modify serum lipid concentrations beyond what is achieved with standard care. More than 34% of the American adult population alone meets the criteria for metabolic syndrome.